{"downloaded": true, "htmlmade": false, "full": {"id": "29740809", "source": "MED", "pmid": "29740809", "pmcid": "PMC6074026", "fullTextIdList": {"fullTextId": "PMC6074026"}, "doi": "10.1111/bjh.15261", "title": "A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.", "authorString": "O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.", "authorList": {"author": [{"fullName": "O'Donnell EK", "firstName": "Elizabeth K", "lastName": "O'Donnell", "initials": "EK", "authorId": {"@type": "ORCID", "#text": "0000-0002-4042-1526"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA."}, {"affiliation": "Harvard Medical School, Boston, MA, USA."}]}}, {"fullName": "Laubach JP", "firstName": "Jacob P", "lastName": "Laubach", "initials": "JP", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}]}}, {"fullName": "Yee AJ", "firstName": "Andrew J", "lastName": "Yee", "initials": "AJ", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA."}, {"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Mass General/North Shore Cancer Center, Danvers, MA, USA."}]}}, {"fullName": "Chen T", "firstName": "Tianqi", "lastName": "Chen", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}}}, {"fullName": "Huff CA", "firstName": "Carol Ann", "lastName": "Huff", "initials": "CA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Johns Hopkins Hospital, Baltimore, MD, USA."}}}, {"fullName": "Basile FG", "firstName": "Frank G", "lastName": "Basile", "initials": "FG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Cape Cod Hospital, Hyannis, MA, USA."}}}, {"fullName": "Wade PM", "firstName": "Philip M", "lastName": "Wade", "initials": "PM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Cape Cod Hospital, Hyannis, MA, USA."}}}, {"fullName": "Paba-Prada CE", "firstName": "Claudia E", "lastName": "Paba-Prada", "initials": "CE", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}]}}, {"fullName": "Ghobrial IM", "firstName": "Irene M", "lastName": "Ghobrial", "initials": "IM", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}]}}, {"fullName": "Schlossman RL", "firstName": "Robert L", "lastName": "Schlossman", "initials": "RL", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}]}}, {"fullName": "Burke JN", "firstName": "Jill N", "lastName": "Burke", "initials": "JN", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA."}}}, {"fullName": "Harrington CC", "firstName": "Cynthia C", "lastName": "Harrington", "initials": "CC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA."}}}, {"fullName": "Lively KJ", "firstName": "Kathleen J", "lastName": "Lively", "initials": "KJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA."}}}, {"fullName": "Lyons HF", "firstName": "Hannah F", "lastName": "Lyons", "initials": "HF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Mass General/North Shore Cancer Center, Danvers, MA, USA."}}}, {"fullName": "Munshi NC", "firstName": "Nikhil C", "lastName": "Munshi", "initials": "NC", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}]}}, {"fullName": "Anderson KC", "firstName": "Kenneth C", "lastName": "Anderson", "initials": "KC", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}]}}, {"fullName": "Trippa L", "firstName": "Lorenzo", "lastName": "Trippa", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}}}, {"fullName": "Richardson PG", "firstName": "Paul G", "lastName": "Richardson", "initials": "PG", "authorId": {"@type": "ORCID", "#text": "0000-0002-7426-8865"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Harvard Medical School, Boston, MA, USA."}, {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}]}}, {"fullName": "Raje NS", "firstName": "Noopur S", "lastName": "Raje", "initials": "NS", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA."}, {"affiliation": "Harvard Medical School, Boston, MA, USA."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-4042-1526"}, {"@type": "ORCID", "#text": "0000-0002-7426-8865"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "2", "volume": "182", "journalIssueId": "2704517", "dateOfPublication": "2018 Jul", "monthOfPublication": "7", "yearOfPublication": "2018", "printPublicationDate": "2018-07-01", "journal": {"title": "British journal of haematology", "ISOAbbreviation": "Br J Haematol", "medlineAbbreviation": "Br J Haematol", "NLMid": "0372544", "ISSN": "0007-1048", "ESSN": "1365-2141"}}, "pubYear": "2018", "pageInfo": "222-230", "abstractText": "We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1\u00b73\u00a0mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73\u00a0years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35\u00b71\u00a0months (95% confidence interval 30\u00b79-not reached) and median OS was not reached at a median follow-up of 30\u00a0months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.", "affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article"]}, "grantsList": {"grant": {"grantId": "P01 CA155258", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Dexamethasone", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Administration, Oral"}, {"majorTopic_YN": "N", "descriptorName": "Administration, Cutaneous"}, {"majorTopic_YN": "N", "descriptorName": "Drug Administration Schedule"}, {"majorTopic_YN": "N", "descriptorName": "Prospective Studies"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Kaplan-Meier Estimate"}, {"majorTopic_YN": "N", "descriptorName": "Bortezomib", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Patient Reported Outcome Measures"}, {"majorTopic_YN": "N", "descriptorName": "Lenalidomide", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}]}, "keywordList": {"keyword": ["Multiple myeloma", "Transplant-ineligible"]}, "chemicalList": {"chemical": [{"name": "Dexamethasone", "registryNumber": "7S5I7G3JQL"}, {"name": "bortezomib", "registryNumber": "69G8BD63PP"}, {"name": "lenalidomide", "registryNumber": "F0P408N6V4"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15261"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6074026"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6074026?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15261"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "28", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS982347", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-06-03", "dateOfCreation": "2018-05-10", "firstIndexDate": "2018-05-10", "fullTextReceivedDate": "2020-10-15", "dateOfRevision": "2019-06-03", "electronicPublicationDate": "2018-05-08", "firstPublicationDate": "2018-05-08"}, "abstract": "We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1\u00b73\u00a0mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73\u00a0years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35\u00b71\u00a0months (95% confidence interval 30\u00b79-not reached) and median OS was not reached at a median follow-up of 30\u00a0months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.", "Keywords": ["Multiple myeloma", "Transplant-ineligible"], "journaltitle": "British journal of haematology", "authorinfo": ["O'Donnell EK", "Laubach JP", "Yee AJ", "Chen T", "Huff CA", "Basile FG", "Wade PM", "Paba-Prada CE", "Ghobrial IM", "Schlossman RL", "Burke JN", "Harrington CC", "Lively KJ", "Lyons HF", "Munshi NC", "Anderson KC", "Trippa L", "Richardson PG", "Raje NS"], "title": "A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma."}